S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

Novartis SEC Filings & 10K Form (NYSE:NVS)

$92.99
-0.07 (-0.08 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$92.65
Now: $92.99
$93.29
50-Day Range
$87.08
MA: $90.00
$93.09
52-Week Range
$72.19
Now: $92.99
$95.00
Volume1.37 million shs
Average Volume2.14 million shs
Market Capitalization$213.11 billion
P/E Ratio18.27
Dividend Yield1.98%
Beta0.6

SEC Filings

Novartis (NYSE:NVS) SEC Filings

DateFilerForm TypeView
12/05/2019
6:58 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-T
12/05/2019
5:20 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/25/2019
3:52 PM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-C
11/25/2019
6:32 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-C
11/25/2019
5:30 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/15/2019
4:03 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/12/2019
3:15 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2019
4:23 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/01/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/30/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/22/2019
7:08 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/08/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/02/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/30/2019
5:30 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/17/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/30/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/29/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/18/2019
8:41 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/01/2019
1:20 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/07/2019
6:21 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/31/2019
9:00 AM
Novartis (Filer)
Form SD
Specialized Disclosure Report  
05/30/2019
8:27 PM
BICYCLE THERAPEUTICS plc (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/24/2019
1:35 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/24/2019
1:23 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/22/2019
8:43 PM
BICYCLE THERAPEUTICS Ltd (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/09/2019
5:06 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2019
4:23 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2019
6:03 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2019
12:09 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2019
8:26 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2019
5:26 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/05/2019
4:14 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2019
7:23 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2019
7:09 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/28/2019
4:16 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/22/2019
7:20 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/15/2019
4:25 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/14/2019
6:56 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/26/2019
5:00 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/14/2019
3:02 PM
Intellia Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Institutes for BioMedical Research, Inc. (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
01/30/2019
7:09 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2019
6:31 AM
Novartis (Filer)
Form IRANNOTICE
01/30/2019
6:31 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2019
6:19 AM
Novartis (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
12/21/2018
9:04 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/20/2018
11:41 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/06/2018
4:00 PM
ENDOCYTE INC (Subject)
Novartis (Filed by)
Form DFAN14A
11/05/2018
3:49 PM
ENDOCYTE INC (Subject)
Novartis (Filed by)
Form DFAN14A
10/18/2018
4:17 PM
ENDOCYTE INC (Subject)
Novartis (Filed by)
Form DFAN14A
10/18/2018
4:01 PM
ENDOCYTE INC (Subject)
Novartis (Filed by)
Form DFAN14A
10/18/2018
4:00 PM
ENDOCYTE INC (Subject)
Novartis (Filed by)
Form DFAN14A
10/18/2018
4:00 PM
ENDOCYTE INC (Subject)
Novartis (Filed by)
Form DFAN14A
10/18/2018
10:42 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/18/2018
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/04/2018
3:06 PM
Altimmune, Inc. (Issuer)
Altimmune, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/14/2018
8:14 AM
Altimmune, Inc. (Issuer)
Altimmune, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/06/2018
6:01 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/29/2018
7:13 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/23/2018
10:01 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/22/2018
3:34 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2018
3:07 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2018
4:12 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/16/2018
3:18 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2018
4:05 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2018
5:44 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/10/2018
3:29 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/08/2018
3:21 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2018
3:22 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/02/2018
3:33 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/31/2018
3:16 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/27/2018
3:21 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/27/2018
9:17 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/25/2018
3:35 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2018
3:17 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2018
10:54 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/29/2018
8:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/29/2018
6:27 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/19/2018
4:03 PM
Altimmune, Inc. (Issuer)
Altimmune, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/15/2018
4:11 PM
Altimmune, Inc. (Issuer)
Altimmune, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/01/2018
9:03 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2018
8:38 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/31/2018
8:39 AM
Novartis (Filer)
Form SD
Specialized Disclosure Report  
05/18/2018
8:33 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/17/2018
3:07 PM
Altimmune, Inc. (Issuer)
Altimmune, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/16/2018
10:57 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2018
11:50 AM
AveXis, Inc. (Issuer)
Novartis (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/15/2018
6:01 AM
AveXis, Inc. (Subject)
Novartis (Filed by)
Form SC TO-T/A
05/14/2018
3:01 PM
Aeglea BioTherapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2018
3:28 PM
Aeglea BioTherapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2018
3:01 PM
Aeglea BioTherapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/03/2018
7:20 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/01/2018
7:46 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/01/2018
6:02 AM
AveXis, Inc. (Subject)
Novartis (Filed by)
Form SC TO-T/A
04/23/2018
3:43 PM
Novartis (Reporting)
Novartis Institutes for BioMedical Research, Inc. (Reporting)
Surface Oncology, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/19/2018
9:17 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/19/2018
6:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/18/2018
4:22 PM
Novartis (Reporting)
Novartis Institutes for BioMedical Research, Inc. (Reporting)
Surface Oncology, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
04/18/2018
3:56 PM
Altimmune, Inc. (Issuer)
Altimmune, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel